Skip to content

ALL is aggressive leukemia that occurs most frequently in children and is characterized by the presence of few chromosomal rearrangements and additional mutations.

Dr. Cools’ lab used single-cell targeted DNA sequencing (Tapestri, Mission Bio) and single-cell RNA-sequencing (10x Genomics) to determine the clonal heterogeneity of the leukemia cells of 20 ALL cases at diagnosis and monitored the clonal evolution during chemotherapy treatment. Specifically, the lab designed a custom ALL panel and obtained accurate single-nucleotide variant and small insertion-deletion mutation calling for 305 amplicons covering 110 genes in about 4400 cells per sample and time point. Bone marrow and/or blood samples from 12 B-cell ALL and eight T-cell ALL patients were analyzed.

Dr. Cools will discuss how single-cell DNA amplicon sequencing is a sensitive assay to detect clonal architecture and evolution of the malignant cells in ALL, and present his findings published in the Blood paper, “Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia”.

Jan Cools, PhD
Professor,
VIB Center for Cancer Biology & KU Leuven Center for Human Genetics, Leuven, Belgium

Gema Fuerte, MS
European Field Application Scientist,
Mission Bio

Lei Tong, PhD
Senior Regional Marketing Manager,
Illumina Asia-Pacific Japan

Date & Time
21/10/2021
3:00 PM - 4:00 PM
Location
Singapore
South APAC
Affiliation
VIB Center for Cancer Biology & KU Leuven Center for Human Genetics, Leuven, Belgium
Presenter
Jan Cools, PhD, Professor,
Topic
Cancer Research
Watch Now